Adamas Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €63.51M +36.3% -€48.96M -45.4% -77.1% +1.2 pp -€43.25M -37.2% -68.1% +0.80 pp
    €46.60M +60.5% -€89.72M -19.7% -192.5% +1.9 pp -€68.89M -21.7% -147.8% +1.6 pp
    €29.04M +5,862.5% -€111.74M +46.4% -384.8% +150 pp -€87.99M +57.3% -303.0% +110 pp
    €487.04K -0.2% -€76.33M +49.0% -15,672.5% -52 pp -€55.93M +41.2% -11,483.2% -34 pp
    €487.89K -70.1% -€51.23M +15.9% -10,499.7% -78 pp -€39.61M +1.4% -8,119.6% -57 pp
    €1.63M -96.6% -€44.18M -606.7% -2,703.7% -27 pp -€39.07M -266.7% -2,391.0% -24 pp
    €47.63M -21.4% €8.72M -79.9% 18.3% -0.53 pp €23.44M +1.9% 49.2% +0.11 pp
    €60.64M +89.7% €43.43M +187.1% 71.6% +0.24 pp €23.00M -48.1% 37.9% -1.0 pp
    €31.96M €15.13M 47.3% €44.34M 138.7%

    Notifications